Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
Status:
Completed
Trial end date:
2021-02-24
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of everolimus when given together
with anakinra or denosumab in treating participants with cancers that have spread to other
places in the body and have come back or aren't responding to treatment. Everolimus may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Anakinra is
designated to block a protein that is involved in tumor development, new blood vessels
growing, and the spread of cancer. Monoclonal antibodies, such as denosumab, may interfere
with the ability of tumor cells to grow and spread. Giving everolimus and anakinra or
denosumab may work better in treating participants with advanced cancers.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Denosumab Everolimus Interleukin 1 Receptor Antagonist Protein Sirolimus